A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Phase of Trial: Phase II
Latest Information Update: 30 Nov 2019
Price : $35 *
At a glance
- Drugs Dexamethasone (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 01 Dec 2017 Planned End Date changed from 31 Mar 2026 to 28 Feb 2026.
- 01 Dec 2017 Planned primary completion date changed from 30 Jun 2021 to 31 May 2021.
- 01 Dec 2017 Status changed from not yet recruiting to recruiting.